Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to therapy of papillary thyroid cancer of known BRAF status.

Clinical endocrinology - 1 Dec 2017

Kowalska Aldona, Walczyk Agnieszka, Kowalik Artur, Pałyga Iwona, Gąsior-Perczak Danuta, Trybek Tomasz, Kopczyński Janusz, Kajor Maciej, Mikina Estera, Szymonek Monika, Gadawska-Juszczyk Klaudia, Szyska-Skrobot Dorota, Lizis-Kolus Katarzyna, Hurej Stefan, Chrapek Magdalena, Chłopek Małgorzata, Góźdź Stanisław

Abstract excerpt

OBJECTIVE: A dynamic risk stratification with modified initial estimated risk based on response to therapy and disease course is one of the crucial changes adopted recently by the American Thyroid Association (ATA). This approach focuses on an individualized risk-adapted approach to the management of differentiated thyroid cancer. The BRAF V600E mutation is the most common genetic alteration in papillary thyroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Gland

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 28718951
DOI: 10.1111/cen.13423

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to therapy of papillary thyroid cancer of known BRAF status.PMID 28718951Read ↗

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceSemantic proximity Read ↗

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.Semantic proximity Read ↗

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.Semantic proximity Read ↗

BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).Semantic proximity Read ↗

BRAF V600E Mutations in Papillary Thyroid Carcinoma: Their Relation to Clinical Features and Oncologic Outcomes in A Single Cancer Centre ExperienceSemantic proximity Read ↗

The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.Semantic proximity Read ↗

BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.Semantic proximity Read ↗

[BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].Semantic proximity Read ↗

Association of BRAF Mutation with Treatment Response and Prognostic Factors in Papillary Thyroid Carcinoma: A Retrospective Cohort StudySemantic proximity Read ↗

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.